# PDUFA dates August 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-08

> 32 FDA catalysts are dated in August 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in August 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 2027 | [Avutometinib + defactininb combination primary completion](https://sec-api.dev/pdufa/avutometinib-defactininb-combination) | VSTM | Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer | scheduled | "NCT07747506 (Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-08-01 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07747506)) |
| August 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05120349 (A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05120349)) |
| August 2027 | [Nogapendekin alfa inbakicept (nai) primary completion](https://sec-api.dev/pdufa/nogapendekin-alfa-inbakicept-nai) | IBRX | Sepsis; Septic Shock; Lymphopenia | scheduled | "NCT07578558 (NAI for Sepsis With Persistent Lymphopenia): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-08-03 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07578558)) |
| August 2027 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | scheduled | "NCT05317416 (Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05317416)) |
| August 2027 | [PF-08653945 primary completion](https://sec-api.dev/pdufa/pf-08653945) | PFE | Overweight; Obesity; Overweight and/or Obesity | scheduled | "NCT07575932 (A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575932)) |
| August 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Hemolytic Disease of the Fetus and Newborn | scheduled | "NCT05912517 (A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-05 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05912517)) |
| August 2027 | [QALSODY (tofersen) primary completion](https://sec-api.dev/pdufa/tofersen) | BIIB | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | scheduled | "NCT04856982 (Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-07 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04856982)) |
| August 2027 | [Golcadomide primary completion](https://sec-api.dev/pdufa/golcadomide) | BMY | Large B-cell Lymphoma | scheduled | "NCT06356129 (Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356129)) |
| August 2027 | [Aln-app primary completion](https://sec-api.dev/pdufa/aln-app) | ALNY | Cerebral Amyloid Angiopathy | scheduled | "NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06393712)) |
| August 2027 | [Zigakibart primary completion](https://sec-api.dev/pdufa/zigakibart) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | scheduled | "NCT05852938 (A Study of Zigakibart in Adults With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-10 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05852938)) |
| August 2027 | [Isl primary completion](https://sec-api.dev/pdufa/isl) | MRK | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | scheduled | "NCT06891066 (A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06891066)) |
| August 2027 | [YMI024 primary completion](https://sec-api.dev/pdufa/ymi024) | NVS | Coronary Artery Disease | scheduled | "NCT07830719 (Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-15 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830719)) |
| August 2027 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-small-Cell Lung | scheduled | "NCT05498428 (A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05498428)) |
| August 2027 | [Bms-986489 (atigotatug+nivolumab) primary completion](https://sec-api.dev/pdufa/bms-986489-atigotatug-nivolumab) | BMY | Extensive-Stage Small Cell Lung Cancer | scheduled | "NCT06646276 (A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06646276)) |
| August 2027 | [Zodasiran primary completion](https://sec-api.dev/pdufa/zodasiran) | ARWR | Homozygous Familial Hypercholesterolemia | scheduled | "NCT07037771 (A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-20 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037771)) |
| August 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Obstructive Sleep Apnea | scheduled | "NCT07225686 (Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-20 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225686)) |
| August 2027 | [Hz/su vaccine primary completion](https://sec-api.dev/pdufa/hz-su-vaccine) | GSK | Herpes Zoster | scheduled | "NCT05371080 (A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371080)) |
| August 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS |  | scheduled | "NCT06865651 (Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06865651)) |
| August 2027 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Generalized Myasthenia Gravis; gMG | scheduled | "NCT07596784 (Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596784)) |
| August 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization; Healthy Volunteers | scheduled | "NCT06975878 (Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975878)) |
| August 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Overweight or Obesity and Elevated Liver Fat | scheduled | "NCT07441252 (A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441252)) |
| August 2027 | [Cilta-cel primary completion](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT06550895 (A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06550895)) |
| August 2027 | [Etavopivat primary completion](https://sec-api.dev/pdufa/etavopivat) | NVO | Sickle Cell Disease | scheduled | "NCT06612268 (A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06612268)) |
| August 2027 | [Camlipixant primary completion](https://sec-api.dev/pdufa/camlipixant) | GSK | Refractory Chronic Cough | scheduled | "NCT07650084 (A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07650084)) |
| August 2027 | [MINJUVI (tafasitamab) primary completion](https://sec-api.dev/pdufa/tafasitamab) | INCY | Hematologic Malignancies | scheduled | "NCT06465433 (Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-29 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465433)) |
| August 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obstructive Sleep Apnea | scheduled | "NCT07226765 (Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226765)) |
| August 2027 | [MVASI® (bevacizumab) primary completion](https://sec-api.dev/pdufa/bevacizumab) | ONCY | Ras-mutated Metastatic Colorectal Cancer; mCRC; MSS Metastatic Colorectal Cancer | scheduled | "NCT07446322 (FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-30 (ESTIMATED); Lead Sponsor Oncolytics Biotech." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07446322)) |
| August 2027 | [CTX-009 primary completion](https://sec-api.dev/pdufa/ctx-009) | CMPX | Biliary Tract Cancer; Cholangiocarcinoma; Gall Bladder Cancer | scheduled | "NCT05506943 (A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Compass Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05506943)) |
| August 2027 | [AZD6793 primary completion](https://sec-api.dev/pdufa/azd6793) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT07082738 (A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07082738)) |
| August 2027 | [Telix Pharmaceuticals Ltd primary completion](https://sec-api.dev/companies/tlx/catalysts) | TLX | ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC) | scheduled | "NCT07197580 (Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07197580)) |
| August 2027 | [Piclidenoson primary completion](https://sec-api.dev/pdufa/piclidenoson) | CANF | Lowe Syndrome | scheduled | "NCT07410455 (An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07410455)) |
| August 2027 | [Brelovitug (bjt-778) primary completion](https://sec-api.dev/pdufa/brelovitug-bjt-778) | MIRM | Chronic Hepatitis D | scheduled | "NCT07454837 (Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07454837)) |

Other months: https://sec-api.dev/fda-calendar/2027-07 , https://sec-api.dev/fda-calendar/2027-09. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates August 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-08

```bibtex
@misc{secapidev_fda_calendar_2027_08_20261116,
  title        = {PDUFA dates August 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-08}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_08_20261116","title":"PDUFA dates August 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-08","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
